🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalSouth Korea Ozempic availability — 12 month update Page 3

South Korea Ozempic availability — 12 month update

greg_boulder Sat, Aug 16, 2025 at 6:58 AM 40 replies 1,750 viewsPage 3 of 8
MikeFit_NJ
Senior Member
1,567
6,543
Apr 2024
New Jersey
Aug 22, 2025 at 6:21 AM#11
Dr.ReproEndo said:
The useful move here is to separate what is established from what is widely repeated.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

Last edited: Aug 22, 2025 at 9:21 AM
31 6LeilaHI, marcus_mpls, DeniseRN_TPA and 28 others
Reply Quote Save Share Report
Dr.EM_Chicago
Member
567
2,567
May 2024
Chicago, IL
Aug 22, 2025 at 2:00 PM#12
ChrisMacros said:
Steady state is the thing most people miss.

Saving this. It is the first explanation that did not require me to already understand it. Printing the relevant bit and taking it with me.

30 5matt_MKE, Dr.ReproEndo, lucas_SP_BR and 27 others
Reply Quote Save Share Report
Dr.NutriCornell
Senior Member
1,345
6,234
Mar 2024
Ithaca, NY
Aug 22, 2025 at 9:39 PM#13
Dr.ReproEndo said:
The useful move here is to separate what is established from what is widely repeated.

This is where I part company with the consensus forming above. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

Correct me if the detail matters more than I have assumed.

Last edited: Aug 22, 2025 at 11:39 PM
29 4laura_annarbor, JenMemphis, pat_auckland and 26 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Aug 23, 2025 at 5:18 AM#14

Adding the numbers, since they settle part of this. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

28 3DebRD_ATL, KristenIndy, MarkLI_maint and 25 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Aug 23, 2025 at 12:57 PM#15

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part.

27 2PurityPaulOR, MaxMetOK, MounjBrad and 24 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register